Document is current
Any future updates will be listed below
-
Authors
Jian, Fanchong https://orcid.org/0000-0001-8703-3507
Wang, Jing https://orcid.org/0000-0002-9084-9985
Yisimayi, Ayijiang https://orcid.org/0000-0003-0648-1864
Song, Weiliang
Xu, Yanli
Chen, Xiaosu
Niu, Xiao
Yang, Sijie https://orcid.org/0009-0001-9834-4340
Yu, Yuanling
Wang, Peng
Sun, Haiyan
Yu, Lingling
Wang, Jing
Wang, Yao
An, Ran
Wang, Wenjing
Ma, Miaomiao
Xiao, Tianhe
Gu, Qingqing https://orcid.org/0000-0001-5805-6419
Shao, Fei
Wang, Youchun https://orcid.org/0000-0001-9769-5141
Shen, Zhongyang https://orcid.org/0000-0003-0045-4355
Jin, Ronghua https://orcid.org/0000-0001-8496-172X
Cao, Yunlong https://orcid.org/0000-0001-5918-1078
- License Information
-
More Information
Article History
Received: 18 June 2024
Accepted: 30 October 2024
First Online: 7 November 2024
Competing interests
: Y.C. is listed as an inventor of provisional patent applications of SARS-CoV-2 RBD-specific antibodies. Y.C. is a cofounder of Singlomics Biopharmaceuticals. The remaining authors declare no competing interests.
